NCT05785741 2026-04-06A Study of DB-1310 in Advanced/Metastatic Solid TumorsDualityBio Inc.Phase 1/2 Recruiting1,000 enrolled
NCT04285671 2026-03-10Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung CancerJonsson Comprehensive Cancer CenterPhase 1/2 Active not recruiting30 enrolled
NCT02393248 2023-01-06Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)Incyte CorporationPhase 1/2 Terminated201 enrolled 71 charts
NCT05091528 2022-08-18A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersSilverback TherapeuticsPhase 1/2 Terminated2 enrolled 9 charts
NCT04464967 2021-05-12Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNKGen Biotech, Inc.Phase 1/2 Withdrawn
NCT01386580 2015-01-22An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.BBB-Therapeutics B.V.Phase 1/2 Completed84 enrolled